{"article_title": "PhRMA V. HHS Scales Back HRSA Rulemaking Power", "article_keywords": ["hhs", "hrsa", "340b", "district", "power", "scales", "drugs", "rulemaking", "orphan", "phrma", "rule", "entities", "program", "v", "covered", "final"], "article_url": "http://www.law360.com/articles/545512/phrma-v-hhs-scales-back-hrsa-rulemaking-power", "article_text": "PhRMA V. HHS Scales Back HRSA Rulemaking Power\n\nLaw360, New York (June 10, 2014, 12:08 PM ET) -- On May 23, Judge Rudolph Contreras of the U.S. District Court for the District of Columbia ruled[1] that the Health Resources and Services Administration (\"HRSA\") did not have the statutory authority to promulgate its orphan drug final rule.[2] HRSA\u2019s Rule, \u201cExclusion of Orphan Drugs for Certain Covered Entities Under 340B Program,\u201d implemented a provision of the Affordable Care Act that excludes orphan drugs from 340B pricing for the covered entities added to the 340B program by the ACA.[3] Under the final rule, orphan drugs were excluded from the...\n\nTo view the full article, register now.", "article_metadata": {"description": "The U.S. District Court for the District of Columbia recently ruled that the Health Resources and Services Administration did not have the statutory authority to promulgate its orphan drug final rule. As a result, the industry is likely to see another notice or interpretive rule from the agency, rather than a legislative one, say Thomas Barker and Igor Gorlach of Foley Hoag LLP.", "csrf-token": "BmSOwHJIH2XOQmh33NDJo+Lq6N5+xo0a86lJjIoGEePEi9Iip61ewuIAH6c8mHm9lNuFLEI+bulaoWC9NZ34Tg==", "og": {"url": "http://www.law360.com/articles/545512/phrma-v-hhs-scales-back-hrsa-rulemaking-power", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "PhRMA V. HHS Scales Back HRSA Rulemaking Power - Law360"}, "csrf-param": "authenticity_token", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/545512/phrma-v-hhs-scales-back-hrsa-rulemaking-power", "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af36914bd0286fcef3f\"", "article_summary": "[3] Under the final rule, orphan drugs were excluded from the...To view the full article, register now.\n[2] HRSA\u2019s Rule, \u201cExclusion of Orphan Drugs for Certain Covered Entities Under 340B Program,\u201d implemented a provision of the Affordable Care Act that excludes orphan drugs from 340B pricing for the covered entities added to the 340B program by the ACA.\nPhRMA V. HHS Scales Back HRSA Rulemaking PowerLaw360, New York (June 10, 2014, 12:08 PM ET) -- On May 23, Judge Rudolph Contreras of the U.S. District Court for the District of Columbia ruled[1] that the Health Resources and Services Administration (\"HRSA\") did not have the statutory authority to promulgate its orphan drug final rule."}